Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Achille Marino, Teresa Giani & Rolando Cimaz. (2019) Risks associated with use of TNF inhibitors in children with rheumatic diseases. Expert Review of Clinical Immunology 15:2, pages 189-198.
Read now
Read now
Karen van Hoeve, Ilse Hoffman & Severine Vermeire. (2018) Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. Expert Opinion on Drug Safety 17:2, pages 185-196.
Read now
Read now
Ryan S. Funk & Mara L. Becker. (2016) Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy. Expert Review of Precision Medicine and Drug Development 1:1, pages 53-68.
Read now
Read now
Articles from other publishers (18)
Manuel Busto-Iglesias, Lorena Rodríguez-Martínez, Carmen Antía Rodríguez-Fernández, Jaime González-López, Miguel González-Barcia, Begoña de Domingo, Luis Rodríguez-Rodríguez, Anxo Fernández-Ferreiro & Cristina Mondelo-García. (2023) Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review. Pharmaceutics 15:3, pages 766.
Crossref
Crossref
Carlyn V. Kouwenberg, Viera Koopman‐Kalinina Ayuso & Joke H. de Boer. (2021) Clinical benefits and potential risks of adalimumab in non‐JIA chronic paediatric uveitis. Acta Ophthalmologica 100:4.
Crossref
Crossref
Hang Song, Chan Zhao, Junyan Xiao, Fei Gao, Donghui Li & Meifen Zhang. (2022) The Efficacy and Safety of Adalimumab in Treating Pediatric Noninfectious Chronic Anterior Uveitis With Peripheral Retinal Vascular Leakage: A Pilot Study. Frontiers in Medicine 9.
Crossref
Crossref
Hemalatha Srinivasalu, Erin Brennan Treemarcki & Christopher Redmond. (2021) Advances in Juvenile Spondyloarthritis. Current Rheumatology Reports 23:9.
Crossref
Crossref
Hendrik Rusche, Edoardo Marrani, Feliciana Real-Fernandez, Roberta Ponti, Francesco Terzani, Ilaria Maccora, Olivier Monasson, Maria Vincenza Mastrolia, Elisa Peroni, Ilaria Pagnini, Rolando Cimaz, Anna Maria Papini, Gabriele Simonini & Paolo Rovero. (2021) A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis. Scientific Reports 11:1.
Crossref
Crossref
John M. Bridges & Matthew L. Stoll. (2020) Treatment of Juvenile Spondyloarthritis: Where We Stand. Pediatric Drugs 22:6, pages 603-615.
Crossref
Crossref
Hana Malcová. (2020) Recommendations for the Management of Uveitis Associated with Juvenile Idiopathic Arthritis: The Czech and Slovak Adaptation of the Share Initiative. Czech and Slovak Ophthalmology 76:4, pages 182-196.
Crossref
Crossref
Ruud H J Verstegen, Rhona McMillan, Brian M Feldman, Shinya Ito & Ronald M Laxer. (2020) Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review. Rheumatology 59:2, pages 386-397.
Crossref
Crossref
Juliana Barbosa Brunelli, Clovis Almeida Silva, Sandra Gofinet Pasoto, Carla Gonçalves Schahin Saa, Katia Tomie Kozu, Claudia Goldenstein-Schainberg, Elaine Pires Leon, Margarete B. G. Vendramini, Nicole Fontoura, Eloisa Bonfa & Nádia Emi Aikawa. (2019) Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clinical Rheumatology 39:2, pages 515-521.
Crossref
Crossref
Carla Gaggiano, Donato Rigante, Gian Marco Tosi, Antonio Vitale, Bruno Frediani, Salvatore Grosso, Claudia Fabiani & Luca Cantarini. (2019) Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review. Clinical Rheumatology 39:2, pages 327-337.
Crossref
Crossref
Martijn J H Doeleman, Erik M van Maarseveen & Joost F Swart. (2019) Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology 58:10, pages 1839-1849.
Crossref
Crossref
Ariane Klein. (2019) Biologikabehandlung bei der juvenilen idiopathischen ArthritisBiologics in the treatment of juvenile idiopathic arthritis. Zeitschrift für Rheumatologie 78:7, pages 599-609.
Crossref
Crossref
Andrea Skrabl-Baumgartner, Gerald Seidel, Beate Langner-Wegscheider, Axel Schlagenhauf & Jörg Jahnel. (2019) Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Archives of Disease in Childhood 104:3, pages 246-250.
Crossref
Crossref
B Gorovits, D J Baltrukonis, I Bhattacharya, M A Birchler, D Finco, D Sikkema, M S Vincent, S Lula, L Marshall & T P Hickling. (2018) Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clinical and Experimental Immunology 192:3, pages 348-365.
Crossref
Crossref
Achille Marino, Feliciana Real-Fernández, Paolo Rovero, Teresa Giani, Ilaria Pagnini, Rolando Cimaz & Gabriele Simonini. (2018) Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clinical Rheumatology 37:5, pages 1407-1411.
Crossref
Crossref
Rolando Cimaz, Achille Marino & Alberto Martini. (2017) How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmunity Reviews 16:10, pages 1008-1015.
Crossref
Crossref
Sara MuriasLorena MagallaresFatima Albizuri, Dora Pascual-SalcedoErwin Dreesen & Denis Mulleman. (2017) Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics. Therapeutic Drug Monitoring 39:4, pages 370-378.
Crossref
Crossref
Vibeke Strand, Alejandro Balsa, Jamal Al-Saleh, Leonor Barile-Fabris, Takahiko Horiuchi, Tsutomu Takeuchi, Sadiq Lula, Charles Hawes, Blerina Kola & Lisa Marshall. (2017) Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs 31:4, pages 299-316.
Crossref
Crossref